Thank you, operator, and good morning, everyone. Today, I will walk you through our third quarter performance using the same lens we've used all year, which are the six priorities that comprise our strategic plan.

Once I've concluded my commentary, Lindsey will review our financials in detail, after which we'll open the call for questions. Before reviewing performance against each strategic priority, I would like to make clear how delighted we are with our third quarter and year-to-date results.

We are meeting or exceeding our customer creation objectives across the board and remain confident in our ability to execute our strategic plan. Starting with our first priority, which is revenue growth and financial operating leverage.

Third quarter revenue was $75.8 million, up 26.2% from third quarter 2025, with growth in all of our markets. Breast grew more than 50% year-over-year, and extremities, OMF, head and neck combined grew 10.7%.

Avance made up 64% of revenue in the quarter and year-to-date, versus about 60% for 2025. GAAP net income was $2.3 million.

Adjusted net income was $13.1 million, and adjusted EBITDA was $13.4 million, with adjusted EBITDA margin up 2.3 percentage points from a year ago. We ended the quarter with $350 million in cash, cash equivalents, restricted cash, and investments, including proceeds from our September equity offering.

Gross margin was 74.8%, up from 72.7% in the second quarter, and down from 76.6% a year ago. Moving to our second priority, market development.

Consistent with prior quarters, all three target markets contributed positively to third quarter results. We continue to see momentum in breast as nerve reconstruction becomes a larger part of the breast reconstruction conversation.

Growth is coming from expansion within existing accounts, new surgeon adoption, and new account development, supported by rising patient awareness and interest in breast resensation. Because this market remains early in its development, we see significant long-term growth potential from expanding our commercial footprint, developing new accounts, and training new surgeons.

In third quarter, we held our final two surgeon training programs planned for 2026, training more than 50 plastic surgeons in the Resensation technique. We also continued investing in patient awareness and completed significant market development work to prepare for Breast Cancer Awareness Month in October.

We now have roughly 485 active breast accounts, up more than 95 year-over-year, and roughly 590 active surgeons, up more than 140 year-over-year. Turning to extremities and OMF and head and neck markets, growth was double-digit in the third quarter, continuing the steady progress described on prior calls, supported by account expansion and increased surgeon activation, as driven by our high-potential account strategy.

Extremities grew across key indications in both upper and lower extremities. In OMF, head and neck, growth was driven by adoption of our algorithm in mandible reconstruction and continued momentum in oncologic procedures such as neck dissections.

With regards to priority three, commercial expansion, Breast now has 31 representatives and three regional directors, 10 more representatives than at the start of the year. Extremities and OMF and head and neck has 132 representatives and 15 regional directors, 15 more than at the start of the year.

We also have three field-based market development managers supporting OMF and head and neck, and three clinical development managers supporting prostate. The fourth priority of our strategic plan is commercial excellence.

Our primary strategy over the past several years, focusing on high-potential accounts to build enduring nerve care practices, continues to deliver results. In these accounts, our goal is to develop new surgeons and drive adoption of best practices and the full treatment algorithm, making the restoration of peripheral nerve function a standard of care across the hospital.

Year-to-date, high-potential accounts generated 61% of revenue and 55% of growth, with productivity increasing 22%. Productivity in non-high-potential accounts rose 25%, while productivity across all accounts increased 22%.

These results point to broader adoption of nerve care as more surgeons practice across multiple sites, supported by expanded coverage. Next, I'd like to update everyone on our fifth priority, standard of care, evidence, and coverage.

Today, we have two national payer updates to provide. I'll start with Elevance.

In April, Elevance removed Avance from its experimental and investigational list, but included a utilization management criterion based on the nerve gap length from the RECON trial. After a collaborative meeting with Elevance and a few world-leading surgeons in the second quarter, Elevance removed the gap length criteria in August.

This timing beat our internal expectations. Now Aetna.

In early October, Aetna extended coverage to Avance for short- to medium-sensory nerve gaps of 30 millimeters or less in the upper extremity. As we've stated before, it is common for medical policy teams to initially adopt strict utilization management criteria for a new coverage position, and we believe that is what drove Aetna's decision.

Similar to how we've handled the prior Elevance situation, our health economics and reimbursement team will partner with surgeons to educate Aetna and resolve this situation collaboratively. With the updates from Elevance and Aetna, the commercial payer coverage for Avance is approximately 96% of covered lives in the United States.

This satisfies the milestone in our strategic plan for near-universal coverage. Since the second quarter of 2025, we have added an estimated 87.6 million commercial and Medicare Advantage lives across Cigna, Elevance, Aetna, and the 12 Blue Cross Blue Shield regional plans.

Beyond expanding coverage, we continue to invest in the clinical evidence needed to advance nerve repair as an expected standard of care. This quarter, we made progress across that evidence strategy, including new peer-reviewed evidence and advancement of two important clinical studies.

Recently, results from our MATCH study were published, providing direct comparative evidence for Avance nerve graft and nerve autograft in mixed and motor nerve reconstruction. The study demonstrated that motor recovery with Avance was comparable with autograft, further strengthening the body of clinical evidence supporting Avance in mixed and motor nerve repair.

NERVE-RESTORE, which we described last quarter, builds upon this evidence through a randomized, assessor-blinded comparison of Avance nerve graft and sural nerve autograft in mixed and motor nerve repair. We are pleased to report that the first patient has now been enrolled, marking an important milestone in this study.

Additional site activations are planned for the fourth quarter as enrollment continues. We are also advancing EMBRACE, our prospective multicenter study evaluating sensory recovery following breast reconstruction with and without nipple-areolar complex nerve reconstruction.

The study is designed to generate comparative evidence on restoration of nipple-areolar complex sensation, including patient-reported outcomes. Study startup is underway, with the first site initiation planned for the fourth quarter.

Finally, our sixth priority, which is about innovation, R&D, and therapeutic reconstruction. On October 1st, we completed our acquisition of BioCircuit, adding NerveTape as the sixth product in our nerve repair algorithm.

We see significant potential to scale NerveTape as a faster, easier coaptation aid. In large-gap repairs, NerveTape can be used with Avance to connect the proximal and distal nerve ends.

NerveTape also expands our reach into direct repair, an underdeveloped and effectively new opportunity for Axogen that represents approximately 40% to 50% of transected nerve procedures. In these procedures, NerveTape enables surgeons to reconnect a transected native nerve more simply and effectively than with microsuturing, the predominant method used today.

BioCircuit historically sold through approximately 50 independent distributor representatives and served roughly 400 accounts. As of today, Axogen's direct sales organization has assumed all sales and distribution responsibilities.

We expect the transaction to contribute to revenue growth and adjusted EBITDA margin in the first year, while Axogen remains free cash flow positive. Looking ahead, we are confident that leveraging NerveTape across Axogen's direct commercial platform and demonstrating its ability to enable simpler, faster, and more effective repairs will accelerate the adoption of nerve repair and strengthen our overall growth strategy.

Turning to prostate. As announced in this morning's earnings release, we will initiate prostate nerve reconstruction market development in 2027.

Based on collaboration with global experts in urology and men's sexual health, we validated the clinical need, which is substantial, developed a scalable technique that is efficient and reproducible, and see positive clinical outcome signals from our clinical development sites. To date, over 220 patients have received prostate nerve reconstruction with Avance across 15 clinical development sites.

Of these, 117 patients have at least six months of follow-up, 86 grafted on one side unilaterally, and 31 grafted on both sides bilaterally. No graft- or grafting procedure-related complications were reported.

Historically, men undergoing traditional non-nerve-sparing radical prostatectomy have a high risk of severe erectile dysfunction, with unilateral non-nerve-sparing patients reporting recovery of erectile function in only 33% to 56% of men, and those undergoing bilateral non-nerve-sparing procedures having a less than 13% chance of recovering useful erections. When repairing the nerves with Avance, we see that among patients with at least six months of postoperative follow-up, surgeons report that approximately 80% have achieved better than expected recovery of erectile function, defined as a Sexual Health Inventory for Men, or otherwise known as SHIM, score of 15 or higher.

On this validated 25-point scale, a score of 15 or higher is generally associated with erections sufficient for sexual activity. For reference, a score of 7 or lower indicates severe erectile dysfunction.

These early results suggest that meaningful erectile function may return as early as six months after surgery when following postoperative penile rehabilitation protocols, as prescribed, with or without PDE5 inhibitors. In addition, over 95% of patients achieved pad-free urinary continence at or above expected levels.

These results demonstrate an exceptional benefit-to-risk ratio and have established the foundation to initiate prostate nerve reconstruction market development in 2027. We look forward to sharing a detailed overview of the clinical outcomes and market research underlying our decision to move forward on November 9th.

Dr. David Lee, Professor of Urology at the UC Irvine School of Medicine and Director of the University of California, Irvine Health Comprehensive Prostate Cancer Program, and Dr.

Ziho Shen, Assistant Professor of Urologic Surgery at Cleveland Clinic, will join us to provide clinical and patient perspectives. Regarding the financials and logistics of our prostate nerve reconstruction market development plan, we will share details during our March 2027 Investor Day.

We believe nerve reconstruction in prostatectomy can become a meaningful long-term growth driver for Axogen, and more importantly, a new standard of care for men facing prostate cancer. Lastly, as a reminder, prostate is not included in our current or long-range guidance.

We will provide an update on guidance in the first quarter of 2027. To close, we are delighted with our overall business performance and have high confidence in our ability to continue executing our near- and longer-term plans.

With that, I will now turn the call over to Lindsey to review our financials.

Thanks, Mike. I'm pleased to report our third quarter 2026 financial results.

For the third quarter, we reported revenue of $75.8 million, reflecting growth of 26.2% year-over-year. Revenue growth continues to be driven by strong demand for Avance and adoption of our product algorithm across target markets, with unit volume serving as the primary driver, then price.

Our gross profit for the quarter came in at $56.7 million. This represents a gross margin of 74.8%.

Gross margin decreased 180 basis points year-over-year, driven by 3% higher product costs, partially offset by 1.2% lower write-offs. We continue to expect gross margin to decline in the fourth quarter sequentially and to be slightly less than our second quarter, as a result of adjusting our production plans beginning in the third quarter to better align production with the increased demand for long-length Avance, largely stemming from the growth of our breast business.

Yield improvements and pricing actions are underway, but their impact on gross margin will lag as they move through cost of goods sold. We expect full year 2027 to be more in line with full year 2026, and we'll provide formal 2027 guidance in the first quarter.

Operating expenses increased to $55.8 million in the third quarter, up from $44.1 million in the third quarter of 2025, and increased 0.1% of revenue. The increase year-over-year was driven primarily by compensation costs, stock-based compensation expense tied to certain PSUs anticipated to achieve above target on revenue growth components, and costs related to the acquisition of BioCircuit.

Sequentially, as a percentage of revenue, operating expenses decreased 2.3 percentage points. Sales and marketing expenses as a percentage of total revenue decreased 2.7 percentage points to 40% in the third quarter, compared to 42.7% in the third quarter of 2025.

Sequentially, as a percentage of revenue, sales and marketing expenses decreased 4.2 percentage points. Research and development expenses increased 18.3% to $9 million in the third quarter, compared to $7.6 million in the third quarter of 2025, and as a percentage of total revenue decreased to 11.8% from 12.6%.

Sequentially, as a percentage of revenue, research and development expenses decreased 0.5 percentage points. General and administrative expenses increased 51.9% to $16.5 million in the third quarter, compared to $10.8 million in the third quarter of 2025, and as a percentage of total revenue increased 3.6 percentage points to 21.7% from 18.1%.

Sequentially, as a percentage of revenue, general and administrative expenses increased 2.4 percentage points. During the quarter, we incurred $2 million of costs related to our acquisition of BioCircuit, contributing to the year-over-year and sequential increases.

Net income for the third quarter was $2.3 million, or 4 cents per share, compared to $700,000, or 1 cent per share, in the third quarter of 2025. Sequentially, net income improved $3.9 million.

Adjusted net income was $13.1 million, or 21 cents per share, for the third quarter, compared to $6.1 million, or 12 cents per share, for the third quarter of 2025. Sequentially, adjusted net income improved $5.8 million.

Adjusted EBITDA for the third quarter was $13.4 million, compared to an adjusted EBITDA of $9.2 million in the same period last year, and as a percentage of revenue increased 2.3 percentage points to 17.7% from 15.4%. Sequentially, adjusted EBITDA improved $5 million.

Adjusted net income and adjusted EBITDA are calculated as net income or EBITDA adjusted for stock-based compensation, the loss on the extinguishment of debt, and the transaction and integration costs incurred in connection with the acquisition of BioCircuit. The improved bottom-line performance demonstrates our continued ability to drive both top-line growth and profitability.

As of September 30th, 2026, cash, cash equivalents, restricted cash, and investments totaled $350.1 million. Through the first nine months of 2026, we generated $18.9 million of free cash flow.

On October 1st, we completed the acquisition of BioCircuit and funded the purchase price of $200 million plus transaction expenses. Integration and purchase accounting activities are underway and progressing well.

In connection with our purchase accounting for the transaction, we expect to adjust the value of the acquired BioCircuit inventory and recognize goodwill and intangible assets on our balance sheet. Amortization of these intangible assets over their respective lives will significantly increase our amortization expense in general and administration expenses going forward.

Our preliminary purchase price allocation and required disclosures, including pro forma historical revenue and earnings related to the BioCircuit acquisition, will be included in our 2026 Form 10-K. Based on our year-to-date performance, acquisition of BioCircuit, and visibility into the remainder of the year, we are revising our full year 2026 financial guidance.

We now expect full year 2026 revenue growth of at least 29%, or revenue of at least $290 million, including at least $7 million of revenue from BioCircuit. Excluding BioCircuit, we expect organic revenue to be at least $283 million, representing organic growth of at least 26%.

We continue to expect gross margin to be at least 73% and positive free cash flow for the full year. This guidance does not assume material benefit from payer coverage decisions beyond what's already known, nor from our decision to begin market development activities for prostate.

While not expected, our BioCircuit revenue guidance does contemplate some level of integration or disruption risks associated with the acquisition. The expected impact resulting from the overlap of BioCircuit's NerveTape with our Axoguard Connector and Axoguard Protector products is included in our organic revenue growth guidance of at least 26%.

Our gross margin guidance is presented on a GAAP basis, but does not include the potential impact from the purchase accounting adjustments to BioCircuit's inventory value as of the acquisition date, which is currently underway. The resulting step-up in value of the acquired inventory could negatively impact gross margin in the fourth quarter and for the full year relative to our current expectations.

To close, I am pleased with the quarter's results and progress we continue to make improving our profitability. With that, we'll now open the line for questions.

Operator?

Hi, thanks for taking our question. My first question is related to breast, which continues to be a strong driver of growth.

We saw accounts increase year-over-year, and was just curious what share of eligible reconstructions now include Resensation with Axogen's portfolio and how much of this growth is coming from new account activation versus increased utilization within existing accounts?

Sure. With regards to penetration, it's probably around 11%.

We don't know exactly, but it's within that range. In terms of the drivers, it's the basic mechanics of increased same-store sales, i.e., accounts are becoming more productive as they adopt Resensation as a true standard of care.

Most surgeons who go through the initial training and then start, eventually reach a point whereby it's considered a part of any kind of reconstructive procedure. As that happens, their referral networks and otherwise reflect that.

The other element is adding new surgeons within an existing account. Once surgeon begins to practice Resensation as part of their repertoire as a standard of care, invariably other surgeons within the same account will ultimately adopt the same practice.

Then, in addition, adding new accounts. These are the drivers.

Both elements are contributing to the double-digit growth. That's why our priority is expanding footprint so that we can competently and appropriately support the educational process, and then obviously working through the process of opening all accounts.

I guess to put a fine point on it, that's why we continuously say that we expect growth in this area to continue for years as this basic infrastructure and process plays out.

Great, thanks. Then, appreciate that we probably will get more information on the November 9th call, but just on prostate, of the 110,000 robotic prostatectomies a year, how many procedures are you planning to target at launch or can be targeted at launch, and what determines which procedures can be initially targeted?

Jens will take that question.

Our estimated TAM procedure volume is around 110,000 procedures. Obviously, we're not going to target all centers initially.

We're developing the targeting algorithm. We'll be focusing on academic centers, high-volume centers, and centers that do a mix of both unilateral, bilateral reconstructions and nerve-sparing procedures.

Hi, good morning, Mike and Lindsey. This is Ross Osborn on for Larry.

Thanks for taking our questions. To start off, there's been some confusion around how much NerveTape is incremental versus cannibalistic to your business, and we heard Lindsay's comments on 26% organic growth this year.

How should we think about the $34 million in NerveTape sales next year? How much is incremental versus cannibalistic?

Hi, Ross. This is Lindsey.

For next year, the $34 million that I put out in the press release at closing is incremental. That is net of cannibalization.

We'll provide more guidance in the first quarter on 2027.

Great. Then regarding your Aetna coverage update, what share of your Aetna-insured Avance procedures falls inside the policy of shorter than 30 millimeters today?

Then are Aetna breast cases being paid under WHCRA today, or are you seeing denials? Yeah.

Great question, Ross. On the second point, which I'll answer first, in the Aetna policy, they have a footnote that says that federal and state mandates apply, and it's been our experience that Aetna CVS Health intend to comply with WHCRA, and so they pay these claims.

On the first point, we don't break out our procedures by gap length and and whether it's sensory or mixed to motor, but it's a fair number of procedures. Michael talked about in the prepared remarks, our MATCH publication, and we just believe the evidence body supports the coverage criteria that we see from the other payers.

Again, we're confident we can resolve this with surgeons and Aetna's team, and, it's probably in line with next year's annual update, but that work's already underway.

Great. Thank you for taking our questions.

Thanks, Ross.

Good morning, and thanks for taking the questions and congrats on a nice quarter. I guess just to start, the updated guide, when you exclude the BioCircuit contribution, I think that implies 4Q growth of around 27% year-over-year, and that's about a one-point acceleration from 3Q.

Just wanted to get your take on what you're seeing so far in 4Q in your core markets, and where that expected growth acceleration is coming from in 4Q?

Sure, Mike. The growth that we're seeing is really driven by the fundamentals we've mentioned each quarter, which is expand the footprint, that allows you to support more surgeons, open more accounts, and then go deeper within those.

Those basic sales fundamentals are what applies in our opportunity. As we've long discussed, the opportunity to add value from a benefit versus risk value proposition across the spectrum of nerve dysfunction presentation is huge.

That question is really what drives and underlies the whole opportunity. Our job, as we see it, is making sure that we have people present in each of the areas where we have the ability to develop the education process, to drive that process through new surgeon development, education, and the addition of new accounts that are practicing nerve repair.

There's nothing really new under the sun, I guess is the best way to summarize it, is that the math on this, in terms of footprint, just becomes a multiplier effect as that situation expands.

To add a little color on the guidance, sequentially from Q3 to Q4, we don't see a large step-up, we just went based on our normal historical seasonality and our plan in our guide.

Got it. That's helpful.

Thank you both. Then second question is a two-parter.

I guess, first, can you talk about what you're seeing in your experience so far with your sales force selling NerveTape, particularly around how doctors may be transitioning from using Connector to NerveTape? Then the second part of that is, Lindsey, I believe you mentioned the 26% growth guide for this year includes your cannibalization estimate.

Was wondering how you're thinking about that quantitatively and what's baked into the guide for the full year?

With regards to the process of our sales organization representing NerveTape, that's all just underway. All I can really speak to at the moment is great enthusiasm.

People are very excited, and the reasons why we thought that this would be a good fit for the organization, there's nothing that we've experienced thus far to suggest that that original sentiment wasn't well-placed and built on a good foundation. As for the issues or the question about cannibalization, NerveTape is far broader than just Connector, and I think that's very important to emphasize and appreciate, is that there's many different permutations on a technical nerve repair, whether it be direct or otherwise.

While there will be product mix naturally in favor of NerveTape versus Connector, Connector will still continue to be used for specific procedures. NerveTape will obviously be adopted more for large gaps, but then, in particular, the application towards direct repair, where we can eliminate the requirement for microsuturing in a more effective way in a simpler and faster manner.

Nothing's changed in terms of the thesis here, and people will be able to of course measure what we've just expressed in terms of explaining BioCircuit on a quarter-to-quarter basis. We'll publish those results from a pro forma standpoint.

We have high confidence that this will be highly synergistic and appropriately accretive to the business.

When setting the guide for the organic growth, through our research, we modeled just an assumption of what the cannibalization will look like. As we move forward with integrating BioCircuit, we'll continue to challenge those assumptions and see how close we are and adjust as needed, but they are baked in.

We're not going to guide to the exact amount of cannibalization that we are anticipating, but we're just going to disclose the organic growth.

Great. Thank you.

Hi, this is Michael on for Chris. Thank you for taking the question, and congrats on a nice quarter.

I wanted to ask just one question on the NerveTape opportunity. It seems like there are several different levers you could pull on here to drive growth moving forward, and I just wanted to understand what you think is the biggest opportunity.

Is it entering the direct nerve repair procedures, increasing NerveTape utilization in existing Avance cases, or even expanding the population of surgeons willing to use Avance because of the easier procedure? How soon do you think you could capitalize on each of those opportunities, and at which pace?

Thank you.

To be very honest, I know this might be unsatisfying, but it's all of the above. Anytime you can make any procedure more adoptable through ease of use without sacrificing effectiveness, that just basically removes burdens and barriers.

We think it will be enabling of nerve repair in general over time to include people taking on, practicing certain elements of nerve repair that otherwise might not have been able to do so or wouldn't do so because of the microsuturing requirement. That won't happen overnight, but that is part of the strategic rationale.

In terms of it's it's adoption, I think in the in the procedures where it's it's currently gotten its start, OMF, mandible procedures, and then you add into that breast, that will continue to grow for the reasons that it started it started, which is simply makes the procedures more accessible and easier and faster. Then, finally, strategically, direct repair, which is an area that we haven't really had tools that would provide a superior value proposition when you're simply taking a nerve that's been that's suffered a simple transection and you put it back together.

Now with NerveTape, we have the ability to bring a real value there in terms of, again, effectiveness, simplicity, and and and and speed. That all of these are going to contribute to the incremental growth, and we've seen nothing in our early experience to suggest otherwise.

Again, as a reminder, we've been following this asset for quite a while. It's it's not as if we don't have familiarity with it.

Hey, Mike.

Hi, everyone. Thanks for taking our questions, and congrats on another great quarter.

Maybe to start, and apologize if I missed that, can you help quantify what your growth looked like in breast during the third quarter after the 47% growth in the first half?

Higher, lot higher.

It's over, yeah, in the third quarter, the breast growth is over 60%.

Got it. Very helpful.

Thanks. Then just in terms of a follow-up, can you help quantify to what extent you've seen incremental growth coming from your recent commercial wins, and is it fair to think that those commercial wins are having an outsized impact in extremities and OMF, or is breast also benefiting from that equally?

It's very difficult to quantify it, Mike, and part of the reason is kind of a bias analysis, in so far as you know when you have an issue because everyone brings it to your attention, but when it's no longer an issue, no one tells you, 'Hey, it's no longer an issue.' We don't really have the ability to quantify, other than to generalize and say, clearly, our work is enabled in terms of customer creation, simply because there's fewer and fewer coverage and reimbursement issues.

Understood. Thanks very much.

You're welcome.

Hi, congrats on a good quarter, and thanks for taking the questions.

Good morning.

Maybe just some more color on the over 4,000 surgeons I think you noted on the last call that are potentially users of NerveTape. How many of those would be market-expansionary to Axogen, and what kinds of surgeons are you adding there, and what's the medical education strategy over the longer term for you guys there?

Sure. With regard, well, first of all, we've only just begun, we can't report any differences in terms of adoption yet.

It's just too early. In terms of the medical education strategy, the actual technical use of the product is extremely simple, very very low levels of required education.

Where most of the consultative selling and market development will take place will be in best use case scenarios and development. For example, direct nerve repair.

What I mentioned earlier, OMF procedures, where we have individuals who are not necessarily microsurgically trained, but have very difficult procedures where you're trying to reconnect a nerve to a nerve stump in the mandible, those are very difficult and sometimes becomes a barrier to actually doing the nerve part of the procedure. NerveTape enables that through making it much much simpler while by virtue of its form factor.

That's where most of the training will come back. The actual use literally of the tape is like in the movies that we've provided in the links, it's that simple.

Hope that answers your question.

Great, yeah,

and... Jens has

something. I'll give you some additional color on the actual penetration.

If you combine the Axoguard Connector and NerveTape penetration of the overall procedure TAM that we see, it's around 5% today. There's a significant opportunity to grow NerveTape in procedures across all of our markets, as we see both in graft repair and in direct repairs market.

Understood. Then, you also touched briefly on this on your last call relative to Axoguard, but maybe just speak to, again, the economics and the reimbursement landscape for NerveTape.

The proper code for a NerveTape procedure is 64910. That's a nerve repair with a conduit.

I think we updated the corporate deck with also the CMS payments for a direct repair code as well. You can see that there's adequate facility payment to cover the implantables in any procedure like that.

Great, thanks so much.

Thanks, Caitlin.

Hi, good morning. Thanks for taking the question.

Just my first question, just on the sales force kind of productivity and headcount additions, you've pretty much achieved your full-year guidance here in the third quarter as you exit 3Q. How should we think about the pace of rep adds for the remainder of the year?

Productivity took a pretty nice step-up, even ahead of the NerveTape being layered into the bag. Do we just kind of assume similar run rate and kind of layer on NerveTape, or do you see further increases, I guess at least in 4Q, on that front?

We're going to continue to add headcount. We'll come out in Q1 with our guidance for 2027.

As we go into '27, we will be posting for more positions and continue to hire into these roles.

The constraint, as we've mentioned before, in terms of our pace of adds, will be that we don't affect profitability. That said, we see footprint expansion as to be one of the most important levers in the business.

Thanks. Then just strategically on the NerveTape integration and BioCircuit integration, our checks have at least suggest a pretty robust enthusiasm for this product that's the company might not have been able to kind of get through hospitals on their own.

How do we think about the VAC process with existing Axogen contracts, or just the kind of logistics of getting this into doctors' hands now that you own it? Could you maybe provide a little bit of color how you plan on accelerating that?

Thank you.

That's a great question. BioCircuit had around 400 accounts, active accounts.

We have a footprint of close to 3,000 accounts. Given our presence in these accounts and the presence of our portfolio, connections within the facilities, we do believe that we'll be able to accelerate approval in the VAC process for NerveTape.

We definitely believe that we will continue to expand the presence of NerveTape throughout our accounts in the coming months, and that process is already started.

Hi, Jason. Good morning, Mike.

Good morning, Lindsey. Hope you guys are doing well.

Zach Gold on for Jason here. I'll just take a step away from NerveTape for a second here.

Feel like you got a couple of questions on that. I think Lindsey made a comment that '27 margins will be similar to '26.

I don't want to kind of ask for '27 guidance before you're ready. Maybe can you walk us through some of the puts and takes, what helps, what hurts '27 margins?

Does this include any impact from selling prostate? Sort of how did you get to '27 similar to '26 margins?

We're going through right now some pricing initiatives, as well as yield initiatives. As we put those into place, they're just going to take time to be able to go through COGS.

We don't predict right now that we'll see a big uplift in '27 from that, so that's why I've guided the way that I have informally until we get to Q1 and we have pricing baked. With prostate, it does help with our initiatives in production, in terms of just getting more from each donor.

We do see that as being helpful, but again, we won't probably see that in '27.

Got it. That makes sense.

Then on prostate, just to follow up there, I know breast has been a source of margin softness, just given the length of the breast and the, I think Michael you spoke about this last quarter with the COGS proportional. Will you guys see sort of a similar margin dynamic from prostate?

Is it also sort of a disproportionate COGS versus revenue dynamic?

Generally speaking, prostate should be helpful. The grafts are shorter in length, therefore your productivity per donor is better.

The answer to the question is we don't see the same pressure.

Got it. Thank you, guys.

You're welcome.

Thanks, and congrats on a solid quarter. Maybe one on core extremities, and then I'll have a follow-up on prostate.

On core extremities, Mike, maybe could we just kind of go back to those numbers and maybe put an estimate out there of where penetration in that core peripheral market is? I know in the quarter just leading in, there was a little noise in some of the data that was out there, there was some tough comps I think in the September month, but it certainly seems like we're still relatively early in terms of penetration into core extremities.

Just a revisit on those numbers would be helpful, and then I'll have one on prostate.

That's correct, Anthony. We still view that market as underpenetrated.

If you make an adjustment for the case dock from third quarter prior year, our growth in extremities is about 15%. As we look at the business on an ongoing-forward basis, we still believe that extremities will be a business that will range from very high single-digit to low double-digit growth quarter-to-quarter, year-in, year-out, just by virtue of the logistics of the selling process.

Until we see other dynamics that would change that, that's the best way to model the business.

No, very very helpful. On prostate, the initial studies here on da Vinci prostatectomy, 110,000 a year, but you have a pretty big active surveillance prostate population out there of nearly a million patients, and there's certainly intermediate-risk patients out there as well.

When you just think of prostate more broadly beyond DVP, are you going to go after active surveillance, intermediate patients, or should we be thinking about this as exclusive to DVPs, at least for the first few years? Thanks, and congratulations.

Thank you, Anthony. It's first things first.

The value proposition that we can speak to with high confidence is the unilateral or bilateral non-nerve-spared patients. In those situations, we unequivocally bring to bear a value without risk, that there's simply no alternative to or comparison to.

Now, what we expect, and what we've heard from our market research and from surgeons, is that as the potential risk of the cancer intervention itself, shows promise of mitigation, that they expect that more patients will be more willing to first of all, enter into the screening process itself, which is one of the biggest issues is most men just don't even want to know the answer, much less an intervention. These things will take time, awareness will have to build, but everyone believes that this will be a tide that will raise everybody's boats in terms of better cancer care and better screening.

Thanks, Mike.

Thanks, Anthony.

Great. Thank you for taking the questions.

Just one from me, a little bit broader question. Any guideline updates we should be looking for over the next, we'll call it 12 months or so?

I know you've gotten a few this year already, but any other major ones outstanding that are in the relative near term?

Are you referring to clinical guidelines or coverage updates?

Clinical guidelines. Okay.

We don't see any changes to clinical guidelines in the coming 12 months.

Fair enough. Thanks for the questions.

Thanks, Frank.

Thank you, operator. On behalf of the Axogen team, I want to thank everyone for their time and interest in our work to fulfill the promise and potential for all stakeholders of our business purpose, which is to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care.

We look forward to updating you on our continued progress on our earnings call next quarter. Thank you very much.